Back to Journals » Core Evidence » Volume 9

Development of cabozantinib for the treatment of prostate cancer [Corrigendum]

Authors Vaishampayan U

Received 1 May 2014

Accepted for publication 1 May 2014

Published 16 May 2014 Volume 2014:9 Pages 69—70

DOI https://doi.org/10.2147/CE.S67095


Vaishampayan UN. Core Evidence. 2014;9:61–67.
On page 62, line 6 of the Introduction section and page 67, line 2 of the Disclosure statement, "Exelexis Inc." should read "Exelixis Inc.".

Read the original article

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]